With the prevalence of antibiotic resistance on the rise and limited innovation in the novel antibiotic space, alternative reimbursement methods can be considered as a potential approach to stimulating innovation and complementing antibiotic stewardship programmes. In the context of antibiotic resistance, de-linkage of profit and volume through the use of an insurance model has been proposed as a potential strategy to stimulate innovation and curb antibiotic resistance through the availability of novel antibiotics.